The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 29, 2020
Filed:
May. 15, 2018
Applicant:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Allison Berger, Arlington, MA (US);
Eric S. Lightcap, Natick, MA (US);
Assignee:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/555 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2019.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/555 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01);
Abstract
Disclosed are methods for the treatment of various solid tumors in patients in need of such treatment. The methods comprise administering to such a patient an NEDD8-activating enzyme (NAE) inhibitor such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. Also disclosed are medicaments for use in the treatment of various solid tumors.